TARK advised Estonian companies and universities on co-operation in the development of SARS-Cov-2 BioBlock nasal and throat spray based on antibodies against SARS-CoV-2 coronavirus

The team of law firm TARK, led by partner Hannes Küün, advised the consortium consisting of Icosagen Grupp, AS Chemi-Pharm, University of Tartu (Institute of Pharmacy, Institute of Biomedicine and Translational Medicine, and Institute of Technology), Estonian University of Life Sciences (Institute of Veterinary Medicine and OÜ Eerika farm) and OÜ Teadus ja Tegu that have collaborated to develop and patent a technology for the creation of a colostrum preparation with anti-infective effect against coronavirus (the product). The consortium plans to conduct clinical trials in Estonia and launch a nasal and throat spray “SARS-CoV-2 BioBlock” containing the product.

In co-operation with Estonian companies and universities, a technology was developed that can be used to prepare a nasal and throat spray based on antibodies against SARS-CoV-2, which has shown its effectiveness in preventing coronavirus infection during initial research.

We look forward to clinical trials and the start of production of “SARS-CoV-2 BioBlock” nasal and throat spray containing the product.

Read more: